sacituzumab
gilead
['sacituzumab', 'breast', 'mbc', 'tropics-02', 'sacitu, govi']
#asco23 | hall b1| mon 12:30pm ct
final overall survival (os) analysis from the phase 3 tropics-02 study of sacituzumab govitecan (sg) in patients (pts) with hormone receptor positive/her2-negative (hr+/her2 ) metastatic breast cancer (mbc) 
The official Twitter account for Mass General Cancer Center, a member of Mass General Brigham.